PTC Therapeutics (PTCT) Tops Q1 EPS by 43c, provides guidance

PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($0.03), $0.43 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $273 million versus the consensus estimate of $224.08 million.

GUIDANCE:

PTC Therapeutics sees FY2026 revenue of $1.08-1.18 billion, versus the consensus of $990.8 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Apple investigating exposure to Tata Electronics data breach, full analysis underway - Reuters
• Eva Live forms cybersecurity task force through Eva Defense unit
• CBD of Denver Announces Updated Corporate Website Reflecting Strategic Pivot into Artificial Intelligence